Latest News and Press Releases

CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...

- Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy- Submitted IND application for SRK-181, a potent and selective...

Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...

CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...

Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData...

Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endAccelerated initiation of Phase 1...

CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...

CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...